|
Monday 12th September 2022 |
Text too small? |
Synlait Milk Limited (Synlait) provides an update on the re-registration process for its State Administration for Market Regulation (SAMR) licence for The a2 Milk Company’s Chinese labelled 至初® Infant Formula.
Synlait has received notification from SAMR that the company’s current registration has been renewed. The renewal allows Synlait to manufacture Chinese labelled 至初® Infant Formula until 21 February 2023 under the previous GB standard.
In parallel, Synlait is working towards achieving its re-registration under the new GB (food safety legislation). The new GB recipe registration timeline and process has been impacted by China’s COVID-19 lockdowns.
Synlait is working with The a2 Milk Company on stock transition plans. Synlait does not anticipate current forecasted volumes of China-label a2 Platinum® Infant Formula to be impacted by changes to the re-registration timetable. Positive and constructive engagement with SAMR officials is ongoing.
Synlait CEO Grant Watson commented: “We are very pleased SAMR has renewed our current China registration. Gaining re-registration for the new GB recipe is a top priority for Synlait and The a2 Milk Company.”
Announcement: Synlait provides SAMR update; current registration renewed
No comments yet
RAK - 1H26: Strong first half growth and strategic momentum
Green Cross Health Interim Results to 30 September 2025
Devon Funds Morning Note - 28 November 2025
November 28th Morning Report
Pacific Edge Appoints Chief Commercial Officer
Ryman Healthcare reports 1H26 results
Tower reports record FY25 result, increased dividends
NZ King Salmon Investments Ltd releases FY25 (Sept) results
RBNZ - OCR lowered to 2.25%
SVR - Savor Interim Results and Trading Update